10-QPeriod: Q2 FY2001

BIOGEN INC. Quarterly Report for Q2 Ended Jun 30, 2001

Filed August 13, 2001For Securities:BIIB

Summary

IDEC Pharmaceuticals Corporation's 10-Q filing for the period ending June 30, 2001, demonstrates robust revenue growth, primarily driven by its flagship product, Rituxan. Total revenues for the six months ended June 30, 2001, surged to $121.4 million from $66.0 million in the prior year, largely due to a significant increase in revenues from unconsolidated joint business, which more than doubled to $106.6 million. This growth reflects expanded market penetration for Rituxan and a more favorable profit-sharing arrangement with Genentech that began in Q1 2001. The company is also progressing with its lead product candidate, ZEVALIN™, submitting additional information to the FDA in July 2001 following a Complete Review Letter. While ZEVALIN faces a critical review by an advisory committee in September 2001, the FDA has acknowledged the resubmission as complete, indicating potential approval within six months. Financially, IDEC maintains a strong liquidity position with $453.9 million in cash and cash equivalents and $158.6 million in securities available for sale as of June 30, 2001. However, the company is making substantial investments in its future, including plans for a large-scale manufacturing facility estimated at $300-$400 million over four years, which may be financed through off-balance sheet lease arrangements.

Key Highlights

  • 1Total revenues for the six months ended June 30, 2001, increased to $121.4 million, up from $66.0 million in the same period of 2000, driven by strong performance of Rituxan and favorable profit-sharing with Genentech.
  • 2Revenues from unconsolidated joint business, primarily related to Rituxan, more than doubled to $106.6 million for the six months ended June 30, 2001, compared to $53.2 million in the prior year.
  • 3ZEVALIN™ received a Complete Review Letter from the FDA in May 2001, and the company submitted additional information in July 2001. The FDA acknowledged the resubmission as complete, with a potential review decision within six months.
  • 4The company's cash and cash equivalents significantly increased to $453.9 million as of June 30, 2001, up from $401.1 million at the end of 2000, indicating a strong liquidity position.
  • 5Operating expenses increased, with Research and Development expenses rising to $43.2 million (six months ended June 30, 2001) from $31.8 million (six months ended June 30, 2000), reflecting ongoing development efforts.
  • 6Selling, general, and administrative expenses also grew to $23.1 million (six months ended June 30, 2001) from $12.7 million (six months ended June 30, 2000), likely in anticipation of ZEVALIN's potential commercialization.
  • 7The company is planning to build a large-scale manufacturing facility in Oceanside, estimated to cost $300-$400 million over four years, indicating significant future investment in production capabilities.

Frequently Asked Questions

The primary driver of IDEC's revenue growth is the strong performance of its flagship product, Rituxan. Revenues from the unconsolidated joint business, which includes profit sharing from Rituxan sales in the U.S. with Genentech, saw a significant increase. This was further boosted by a more favorable profit-sharing tier implemented in Q1 2001.

IDEC submitted a Biological License Application (BLA) for ZEVALIN™ which received a Complete Review Letter from the FDA in May 2001. The company submitted additional information in July 2001, and the FDA has acknowledged this as a complete resubmission. ZEVALIN™ is scheduled for review by the Oncologic Drugs Advisory Committee (ODAC) on September 11, 2001. The FDA has up to six months from the resubmission date to make a decision.

IDEC maintains a strong liquidity position, with cash and cash equivalents totaling $453.9 million as of June 30, 2001. The company believes its current resources, along with anticipated funds from its Genentech collaboration, are sufficient for its foreseeable future. However, it plans to invest significantly ($300-$400 million over four years) in a new large-scale manufacturing facility, which may be financed through off-balance sheet lease arrangements, indicating potential future capital requirements.

The company highlights significant risks, including its heavy reliance on Rituxan sales, which constitute a substantial majority of its revenue. Other key risks include the uncertainty of clinical trial results for its products under development, potential challenges in obtaining regulatory approvals (especially for ZEVALIN™), limited manufacturing experience and reliance on third parties, intense industry competition, and intellectual property protection.